Flanvotumab Biosimilar - Research Grade (ICH5553-10mg)

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

This product (ICH5553) is a recombinant, unconjugated non-therapeutic analog of flanvotumab, a fully human IgG1-kappa monoclonal antibody directed against tyrosinase-related protein 1 (TYRP1, also called TRP1 or gp75). It is supplied for research use only and is not the clinical drug; it is not intended for human or veterinary use. Because TYRP1 is a melanocyte- and melanoma-associated cell-surface antigen, a flanvotumab-analog antibody is a useful reagent for probing TYRP1 biology and for melanoma-focused antibody research. Typical applications include use as a defined, sequence-characterized binder for detecting or capturing surface TYRP1, as a benchmark or isotype-matched reference in binding and effector-function assays, as a positive control in method development, and as a targeting scaffold in ADCC or antibody-drug-conjugate development workflows. The recombinant format gives lot-to-lot consistency. Material is offered at research grade (low endotoxin, typically <1 EU/mg) with ultra-low-endotoxin (<0.5 EU/mg) and bulk milligram-to-gram quantities available to support in-vitro screening and preclinical study designs. TYRP1 (tyrosinase-related protein 1; gene TYRP1, UniProt P17643), historically known as TRP1 or the gp75 antigen, is a type I melanosomal membrane glycoprotein and a member of the tyrosinase family of copper-binding oxidoreductases. It is expressed almost exclusively in melanocytes and melanoma cells, where it localizes to the melanosome and participates in the eumelanin (black-brown pigment) biosynthetic pathway; in human melanocytes it contributes to the later oxidation/stabilization steps and helps maintain melanosome integrity. TYRP1 also physically associates with and stabilizes tyrosinase, protecting melanocytes from tyrosinase-mediated toxicity. Its restricted, lineage-specific expression and presence at the cell surface on melanoma cells make TYRP1 an attractive tumor-associated antigen. Loss-of-function TYRP1 mutations cause oculocutaneous albinism type 3.